AVEO Pharmaceuticals, Inc. (AVEO)
(Delayed Data from NSDQ)
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO (AVEO) Up 25.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of -150.00% and -67.93%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.
AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 11.8% in Session
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) was a big mover last session, as the company saw its shares rise more than 11% on the day amid huge volumes.
Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
Why Is AVEO Pharmaceuticals (AVEO) Down 1.6% Since Its Last Earnings Report?
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
by Zacks Equity Research
Surging implied volatility makes AVEO Pharmaceuticals (AVEO) lucrative to the option traders.
AVEO Down 7.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
AVEO reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
by Zacks Equity Research
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.
AVEO Pharmaceuticals (AVEO) Q4 Loss Wider, Revenues Miss
by Zacks Equity Research
AVEO Pharma (AVEO) posted wider-than-expected loss in the fourth quarter of 2017. Revenues missed estimates and were also lower than year ago figure.
AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.
AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
by Zacks Equity Research
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
by Zacks Equity Research
Investors in AVEO Pharmaceuticals (AVEO) need to pay close attention to the stock based on moves in the options market lately.
AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
by Zacks Equity Research
AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.
Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?
by Zacks Equity Research
AVEO Pharmaceuticals received approval for its first drug, Fotivda, as first-line treatment for RCC in Europe during the quarter. This is likely to have a favorable impact on third-quarter results.
AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.
AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) depends on collaboration revenues and milestone and other payments for its top line. The CHMP recommendation for tivozanib MAA received during the quarter was a positive.
Company News for July 10, 2017
by Zacks Equity Research
Companies in the News are: BRK.A,SPA,AVEO,ABCO,UNH
AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8%
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) shares rose around 15% in the last trading session.